Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-28
1999-09-14
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514318, 514357, 546122, 546193, 546337, A61K 31435, C07D47104
Patent
active
059523417
ABSTRACT:
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
REFERENCES:
patent: 5260277 (1993-11-01), McKenzie
patent: 5391466 (1995-02-01), Ueda et al.
patent: 5455243 (1995-10-01), Duggan et al.
patent: 5534524 (1996-07-01), Bonewald et al.
patent: 5665358 (1997-09-01), Barton et al.
patent: 5668159 (1997-09-01), Jin et al.
patent: 5674965 (1997-10-01), Carey et al.
patent: 5763408 (1998-06-01), Nishikawa et al.
Fujii et al., Chemical Abstracts, vol. 128, abstract 278737, 1998.
Bihovsky et al., Chemical Abstracts, vol. 123, abstract 56535, 1995.
Seitz et al., Chemical Abstracts, vol. 123, abstract 257291, 1995.
Ali et al., Chemical Abstracts, vol. 118, abstract 7397, 1993.
Alig et al., Chemical Abstracts, vol. 116, abstract 129634, 1992.
Zablocki et al., J. Med. Chem. (1995), vol. 38, pp. 2378-2394, "Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen."
Rico et al., J. Org. Chem. (1993), vol. 58, pp. 7948-7951, "A highly stereoselective michael addition to an .alpha., .beta.-unsaturated ester as the crucial step in the synthesis . . . ".
Duggan Mark E.
Hartman George D.
Durette Philippe L.
Merck & Co. , Inc.
Raymond Richard L.
Sabatelli Anthony D.
Winokur Melvin
LandOfFree
Integrin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1510003